Disseminated cutaneous histoplasmosis
ICD-10 B44.2 is a billable code used to indicate a diagnosis of disseminated cutaneous histoplasmosis.
Disseminated cutaneous histoplasmosis is a systemic fungal infection caused by the organism Histoplasma capsulatum, which primarily affects the lungs but can disseminate to other organs, including the skin. This condition is particularly prevalent in immunocompromised individuals, such as those with HIV/AIDS, organ transplant recipients, or patients undergoing immunosuppressive therapy. Clinically, it presents with various skin lesions, which may include papules, plaques, or ulcers that can be mistaken for other dermatological conditions. Diagnosis is typically confirmed through culture, serology, or histopathological examination of skin biopsies. Treatment often involves antifungal therapy, with itraconazole being the first-line agent for mild to moderate cases, while severe cases may require amphotericin B. Early recognition and treatment are crucial to prevent further dissemination and complications, especially in vulnerable populations.
Detailed patient history, including immunocompromised status and clinical presentation.
Patients presenting with skin lesions and a history of exposure to Histoplasma.
Ensure all lab results and treatment plans are documented clearly.
Comprehensive descriptions of skin lesions and any relevant biopsy results.
Patients with atypical skin lesions that may be fungal in origin.
Differentiating between histoplasmosis and other dermatological conditions.
Used when a biopsy is performed to confirm the diagnosis of disseminated cutaneous histoplasmosis.
Document the reason for the biopsy and the findings.
Ensure the pathology report is included in the patient's medical record.
The primary treatment is antifungal therapy, with itraconazole being the first-line treatment for mild to moderate cases, while severe cases may require amphotericin B.
